The TRANSFORMER project has made significant progress in advancing plasma-based therapies, bringing them closer to a viable clinical solution. Our research has not only validated the technical feasibility of using plasma-treated liquids and hydrogels as delivery systems, but also advanced in the development of IP, regulatory and technology transfer strategies, along with market analysis and business plans, have been key for the effective advancement of the technology. In this regard, the objectives related to the assessment of the commercial viability have been accomplished and are the following:
1. Regulatory position and analysis: The regulatory landscape was evaluated to identify potential hurdles and ensure compliance with existing medical device regulations. A viability analysis and two regulatory pathways for our two patents were developed with the help of a specialized consultancy. This step was crucial to outline the pathway to clinical trials and adapt our strategy from early stages.
2. IP position and strategy: Our two patents (WO 2021/255179 and WO 2022/112206) are currently in National Phases. A detailed roadmap has been developed to highlight the next steps and required payments to secure the protection in the designated countries. A thorough analysis of the IP landscape has been performed, with a Freedom To Operate (FTO) search and an IP strategy to avoid infringements.
3. Market analysis: A detailed market analysis was conducted to understand the potential demand for our technology, identify key stakeholders, and evaluate the competitive landscape. This analysis helped in refining the value proposition and business model.
4. Technology transfer position and strategy: Several strategies have been studied for transferring the technology from the research phase to clinical application. This included identifying potential industry partners, exploring licensing opportunities, and planning for future collaborations.
The commercial need for such an innovation is evident across several dimensions. This disruptive technology has the potential to address the current unmet needs in osteosarcoma treatment, including high relapse rates, the necessity for high chemotherapy doses, and the frequency of secondary reconstructive surgeries. By providing a localized, less invasive treatment option, the physical and psychological burden on patients can be reduced, while providing more efficient treatment options for clinicians. The proposed solution also stands to redefine the economic landscape of cancer care through direct cost savings, enhanced patient outcomes leading to reduced indirect costs, and stimulate growth within the biotechnology and healthcare industries. Furthermore, the environmental impact of the technology can be seen as part of a broader movement towards more sustainable medical treatments, minimizing resource utilization, and reducing the chemical waste related to the current treatments.
Looking forward, several key steps are needed to ensure the successful uptake and commercialization of this technology. Further research and development will refine treatment protocols and confirm long-term safety and efficacy. Fundraising efforts will be essential for technological progress and exploitation. The creation of a spin-off company will facilitate market introduction and business operations. Ongoing stakeholder engagement will support the adoption and integration of the technology into clinical practice. Maintaining a robust intellectual property strategy will protect our technology in the designated countries and secure competitive advantage.
In conclusion, the TRANSFORMER project has laid a strong foundation for a novel, dual-function cancer therapy that promises significant benefits for patients and the healthcare system. By continuing to build on these achievements, more effective, less invasive treatments for osteosarcoma and potentially other cancer types can be developed, ultimately transforming the landscape of cancer care.
